A246960 Share Price Performance
₩2,645.00
382.50 (16.91%)
Price ₩2,645.00
Share Price₩2,645.00
A246960 Community Narratives
There are no narratives available yet.
Recent A246960 News & Updates
No updates
SCL Science Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -139.22
- Gross Margin
- 25.77%
- Net Profit Margin
- -80.56%
- Debt/Equity Ratio
- 75.5%
SCL Science Inc. Competitors
About A246960
- Founded
- 2010
- Employees
- 62
- CEO
- WebsiteView website
SCL Science Inc. produces medical hemostatic agents using biomimetic technology. Its products includes BiMM (Bio-inspired Medical Materials) that reacts immediately with blood; Endoseal which is used for the specialized indication of gastrointestinal bleeding; InnoSeal, a hemostatic agent that is used in various surgical fields such as cardiology, radiology, and neurosurgery; Jelly Seal, a hemostasis and sealing products; STOP, a non-bleeding intravascular injection; Film that prevents leakage at intestinal and vascular anastomosis sites; and InnoLOCK and InTro, a vascular interventional procedure items, as well as operates bio-logistics business. The company also engages in conducting clinical trial analysis services related to new drug development, in vitro diagnostic medical device performance evaluation, transportation of pharmaceuticals and clinical trial samples, etc. The company was formerly known as InnoTherapy, Inc. and changed its name to SCL Science Inc. in March 2024. SCL Science Inc. was founded in 2010 and is headquartered in Seoul, South Korea.
South Korean Market Performance
- 7 Days: -1.1%
- 3 Months: 22.2%
- 1 Year: 23.5%
- Year to Date: 30.6%
Over the past 7 days, the market has dropped 1.1% with the Materials sector contributing the most to the decline. In contrast to the last week, the market is actually up 24% over the past year. Earnings are forecast to grow by 22% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading